Nerofe

DRUG4 trials

Sponsors

Immune System Key Ltd, Georgetown University

Conditions

AMLAcute Myelogenous LeukemiaAdvanced MDSCancerKRAS Mutation-Related TumorsMyelodysplastic SyndromesSolid Tumor

Phase 1

Phase 1 Trial of Intravenously Administered Nerofe™ in Subjects With Advanced Malignancies

CompletedNCT01690741

Immune System Key LtdCancer

Start: 2013-12-31End: 2017-12-19Updated: 2018-06-25

Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML

RecruitingNCT04365179

Immune System Key LtdAdvanced MDS, AML

Start: 2020-06-18End: 2025-08-30Target: 18Updated: 2024-07-10

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

RecruitingNCT05661201

Georgetown UniversityKRAS Mutation-Related Tumors, Solid Tumor

Start: 2023-04-12End: 2027-01-01Target: 24Updated: 2026-03-06

Phase 2

A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS

WithdrawnNCT03059615

Immune System Key LtdAcute Myelogenous Leukemia, Myelodysplastic Syndromes

Start: 2018-10-25End: 2020-07-26Updated: 2020-07-31

Related Papers

Nerofe+ldDox releases c-Jun from nuclear ST2 to reprogram the immune microenvironment in mtKRAS tumors.

2025-12-24

Phase I study of NEROFE and doxorubicin in <i>KRAS</i>-mutated ST2-positive solid tumors.

Journal of Clinical Oncology2023-06-01

A phase 1 trial of a human thymus-expressed apoptosis factor in patients with advanced solid tumors: Interim report.

Journal of Clinical Oncology2015-05-20